Premium
Hydrophilic interaction liquid chromatographic tandem mass spectrometric determination of atenolol in human plasma
Author(s) -
Li Wenkui,
Li Yinghe,
Francisco Diane T.,
Naidong Weng
Publication year - 2005
Publication title -
biomedical chromatography
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.4
H-Index - 65
eISSN - 1099-0801
pISSN - 0269-3879
DOI - 10.1002/bmc.462
Subject(s) - chemistry , chromatography , atenolol , acetonitrile , electrospray ionization , protein precipitation , trifluoroacetic acid , extraction (chemistry) , acetic acid , mass spectrometry , medicine , biochemistry , blood pressure , radiology
A hydrophilic interaction liquid chromatographic method with tandem mass spectrometry for the determination of atenolol, a β ‐blocking agent, in human plasma has been developed and validated over the curve range of 10–2000 ng/mL. The assay was based on protein precipitation followed by evaporation of the extraction solvent, reconstitution with acetonitrile, and chromatography on an Hypersil silica column (50 × 4.6 mm) using a low aqueous–high organic mobile phase. The mobile phase consists of 85% acetonitrile, 15% water, 0.5% acetic acid and 0.04% triuoroacetic acid and runs isocratically at a ow rate of 2.0 mL/min. The column efuent was split so that 50% of it was transferred into the LC‐MS/MS interface operated in positive electrospray ionization mode. The chromatographic run time was 2.0 min per injection. Atenolol and the internal standard, atenolol‐d 7 , showed a retention time of 1.0 min. The inter‐day and intra‐day precision and accuracy of the quality control samples were <5.3% relative standard deviation and <8.0% relative error, respectively. To explore the application of the current method for the analysis of other β ‐blocking agents, propranolol and metoprolol were tested under the same chromatographic conditions with retention times of 0.68 and 0.75 min, respectively. The present method could be used for therapeutic drug monitoring, pharmacokinetic and drug–drug interaction studies of β ‐blocking agents. Copyright © 2005 John Wiley & Sons, Ltd.